🔗 Share this article Users Stopping Weight-Loss Jabs Put On Weight at a Quadrupled Rate Than People Using Diet and Exercise Weight management often requires long-term strategies. Fresh analysis reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs. Published data in a major medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping. "Individuals buying such treatments need to be aware of the risk of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb. Such speed of recovery means a return to starting weight within about one and a half years. Weighing Treatments The research, which looked at 37 of trials involving thousands of participants, compared the outcomes of these new drugs with conventional dieting. Scientists note that individuals who lose weight through diet and exercise typically see a less rapid weight regain—approximately 100 grams monthly—after stopping. Explaining the Quick Regain Doctors propose the way of the injections is key to understanding the accelerated weight return. GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger. "Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication results in hunger is uncontrolled, making overeating a significant risk." An Ongoing Condition? Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. Many experts say that, due to the likelihood of relapse, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like hypertension. Patient Experiences Individuals who have stopped the medication describe a powerful return of hunger. "It felt as if a trigger that goes on and you're instantly extremely hungry," recalled an individual. This challenge is worsened if users have not developed permanent dietary or behavioural modifications during therapy. Significant Interest Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial. Use is more common among females than males. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private prescriptions rather than the NHS. Ultimately, researchers stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing lifestyle support.
Weight management often requires long-term strategies. Fresh analysis reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs. Published data in a major medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping. "Individuals buying such treatments need to be aware of the risk of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb. Such speed of recovery means a return to starting weight within about one and a half years. Weighing Treatments The research, which looked at 37 of trials involving thousands of participants, compared the outcomes of these new drugs with conventional dieting. Scientists note that individuals who lose weight through diet and exercise typically see a less rapid weight regain—approximately 100 grams monthly—after stopping. Explaining the Quick Regain Doctors propose the way of the injections is key to understanding the accelerated weight return. GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger. "Artificially providing GLP-1 concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher. "Withdrawal of this medication results in hunger is uncontrolled, making overeating a significant risk." An Ongoing Condition? Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. Many experts say that, due to the likelihood of relapse, the therapy should be considered life-long. This perspective is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like hypertension. Patient Experiences Individuals who have stopped the medication describe a powerful return of hunger. "It felt as if a trigger that goes on and you're instantly extremely hungry," recalled an individual. This challenge is worsened if users have not developed permanent dietary or behavioural modifications during therapy. Significant Interest Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial. Use is more common among females than males. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private prescriptions rather than the NHS. Ultimately, researchers stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on ongoing lifestyle support.